What is Amneal Pharmaceuticals' operating income?

Amneal Pharmaceuticals' total operating income in 2025 was $394.10 million, based on the following breakdown: Total Gross Profit: $1.11 billion Total Operating Expenses: $719.21 million

Amneal Pharmaceuticals (AMRX) Financials

$17.44 -0.43 (-2.41%)

As of 09/4/2026 04:00 PM Eastern

Compare

Annual Income Statements for Amneal Pharmaceuticals

This table shows Amneal Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	0.00	0.00	-21	-362	91	11	-130	-84	-117	72
Consolidated Net Income / (Loss)	209	169	-201	-604	69	20	-255	-49	-74	128
Net Income / (Loss) Continuing Operations	209	169	-201	-604	69	20	-255	-49	-74	128
Total Pre-Tax Income	215	171	-203	-220	-36	31	-248	-40	-55	139
Total Operating Income	285	245	-20	-249	91	153	-95	204	249	394
Total Gross Profit	597	526	716	353	628	769	785	821	1,020	1,113
Total Revenue	1,018	1,034	1,663	1,626	1,993	2,094	2,212	2,394	2,794	3,019
Operating Revenue	1,018	1,034	1,663	1,626	1,993	2,094	2,212	2,394	2,794	3,019
Total Cost of Revenue	421	507	947	1,273	1,364	1,325	1,428	1,573	1,774	1,905
Operating Cost of Revenue	421	507	947	1,273	1,364	1,325	1,428	1,573	1,774	1,905
Total Operating Expenses	313	281	736	602	537	616	880	616	771	719
Selling, General & Admin Expense	119	109	228	290	327	366	400	430	476	527
Research & Development Expense	179	171	194	188	180	202	200	168	197	194
Other Operating Expenses / (Income)	-	21	16	14	11	7.72	-5.87	-16	-0.93	-5.24
Impairment Charge	0.00	0.00	39	47	2.68	0.71	13	31	0.00	0.00
Restructuring Charge	0.07	9.40	278	51	11	15	2.13	1.75	2.36	4.21
Other Special Charges / (Income)	15	-29	-20	12	5.86	25	271	1.82	97	-0.39
Total Other Income / (Expense), net	-70	-74	-183	28	-127	-121	-153	-245	-304	-255
Interest Expense	0.00	2.53	20	-	0.00	0.00	0.29	41	0.00	31
Interest & Investment Income	-55	-71	-144	-168	-146	-136	-158	-211	-259	-241
Other Income / (Expense), net	-15	-0.19	-20	197	19	15	5.47	6.79	-46	18
Income Tax Expense	5.40	2.00	-1.42	383	-104	11	6.66	8.45	19	11
Net Income / (Loss) Attributable to Noncontrolling Interest	2.05	1.68	-33	-242	-22	9.55	-125	35	43	56
Basic Earnings per Share	$0.00	-	($0.16)	($2.74)	$0.62	$0.07	($0.86)	($0.48)	($0.38)	$0.23
Weighted Average Basic Shares Outstanding	0.00	-	127.25M	132.11M	147.44M	148.92M	150.94M	176.14M	308.98M	313.37M
Diluted Earnings per Share	$0.00	-	($0.16)	($2.74)	$0.61	$0.07	($0.86)	($0.48)	($0.38)	$0.22
Weighted Average Diluted Shares Outstanding	0.00	-	127.25M	132.11M	148.91M	151.82M	150.94M	176.14M	308.98M	324.81M
Weighted Average Basic & Diluted Shares Outstanding	0.00	-	127.25M	132.11M	299.82M	301.54M	303.62M	307.01M	309.97M	314.63M

This table shows Amneal Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-99	-92	5.99	-0.16	-31	12	22	2.37	35	62	58
Consolidated Net Income / (Loss)	-93	-82	17	12	-21	25	36	18	50	78	70
Net Income / (Loss) Continuing Operations	-93	-82	17	12	-21	25	36	18	50	78	70
Total Pre-Tax Income	-83	-76	20	15	-15	37	52	-5.22	55	80	71
Total Operating Income	14	-11	95	89	76	100	111	70	112	142	130
Total Gross Profit	190	238	250	270	263	256	286	274	297	320	335
Total Revenue	617	659	702	702	731	695	725	785	814	723	796
Operating Revenue	617	659	702	702	731	695	725	785	814	723	796
Total Cost of Revenue	427	421	452	433	468	440	438	511	517	402	462
Operating Cost of Revenue	427	421	452	433	468	440	438	511	517	402	462
Total Operating Expenses	176	249	154	181	187	156	175	204	185	178	205
Selling, General & Admin Expense	109	113	116	119	129	118	124	138	146	139	149
Research & Development Expense	50	40	37	63	60	42	50	66	36	40	41
Other Operating Expenses / (Income)	-3.35	0.10	0.00	-1.03	-3.99	-5.12	0.00	-0.12	-0.00	-6.94	-1.30
Restructuring Charge	0.11	1.47	0.22	0.17	0.49	0.57	1.02	0.14	2.47	5.80	8.15
Other Special Charges / (Income)	-11	94	0.70	-0.15	1.78	0.00	-0.39	0.00	-	0.69	8.06
Total Other Income / (Expense), net	-98	-65	-75	-73	-91	-63	-60	-76	-57	-62	-59
Interest Expense	-	-	-	0.00	-	0.00	0.00	31	-	3.51	0.00
Interest & Investment Income	-60	-66	-66	-66	-62	-57	-65	-63	-56	-53	-55
Other Income / (Expense), net	2.70	0.93	-9.35	-7.88	-29	-5.92	5.44	19	-0.56	-4.73	-3.74
Income Tax Expense	9.86	6.16	3.62	3.67	5.42	13	16	-23	5.66	2.18	1.38
Net Income / (Loss) Attributable to Noncontrolling Interest	5.31	9.97	11	12	10	12	13	16	14	16	12
Basic Earnings per Share	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.11	$0.20	$0.18
Weighted Average Basic Shares Outstanding	176.14M	307.28M	309.12M	309.65M	308.98M	311.05M	313.74M	314.17M	313.37M	316.02M	319.20M
Diluted Earnings per Share	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.10	$0.19	$0.18
Weighted Average Diluted Shares Outstanding	176.14M	307.28M	318.96M	309.65M	308.98M	323.96M	322.36M	324.75M	324.81M	328.93M	328.10M
Weighted Average Basic & Diluted Shares Outstanding	307.01M	308.65M	309.54M	309.84M	309.97M	313.42M	314.08M	314.36M	314.63M	319.02M	319.35M

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-29	41	141	-66	194	-90	-222	64	19	195
Net Cash From Operating Activities	115	234	250	1.71	379	242	65	346	295	340
Net Cash From Continuing Operating Activities	115	234	250	1.71	379	242	65	346	295	340
Net Income / (Loss) Continuing Operations	209	169	-201	-604	69	20	-255	-49	-74	128
Consolidated Net Income / (Loss)	209	169	-201	-604	69	20	-255	-49	-74	128
Depreciation Expense	33	46	137	207	235	233	240	229	236	224
Amortization Expense	3.00	4.59	16	43	8.68	9.20	8.60	12	29	22
Non-Cash Adjustments To Reconcile Net Income	26	23	294	109	129	115	133	225	162	172
Changes in Operating Assets and Liabilities, net	-156	-8.51	3.78	246	-63	-136	-62	-72	-59	-205
Net Cash From Investing Activities	-125	-99	-396	-20	-318	-194	-174	-69	-63	-112
Net Cash From Continuing Investing Activities	-125	-99	-396	-20	-318	-194	-174	-69	-63	-112
Purchase of Property, Plant & Equipment	-123	-95	-83	-47	-62	-51	-49	-47	-60	-99
Acquisitions	-1.85	-20	-339	-50	-256	-148	-127	-22	-15	-16
Sale of Property, Plant & Equipment	0.00	0.00	25	-	-	-	-	0.00	0.00	2.09
Divestitures	0.00	16	0.00	35	-	-	0.00	0.00	12	0.00
Net Cash From Financing Activities	-19	-95	288	-46	132	-138	-107	-213	-212	-32
Net Cash From Continuing Financing Activities	-19	-95	288	-46	132	-138	-107	-213	-212	-32
Repayment of Debt	-43	-19	-839	-27	-40	-79	-125	-576	-233	-2,886
Issuance of Debt	225	300	1,325	0.00	180	0.00	85	437	48	2,913
Other Financing Activities, net	-0.26	0.04	-3.76	-19	-4.92	-1.90	-47	-73	-27	-58
Effect of Exchange Rate Changes	-	-	-0.67	-2.25	1.04	0.10	-5.68	0.07	-1.00	-1.68
Cash Interest Paid	51	65	132	159	130	122	143	193	264	198
Cash Income Taxes Paid	4.92	-5.78	35	10	100	-16	13	2.50	15	21

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	3.50	-47	-2.00	29	40	-50	15	155	75	-109	-65
Net Cash From Operating Activities	136	-4.41	40	142	118	7.41	84	118	130	-27	-21
Net Cash From Continuing Operating Activities	136	-4.41	40	142	118	7.41	84	118	130	-27	-21
Net Income / (Loss) Continuing Operations	-93	-82	17	12	-21	25	36	18	50	78	70
Consolidated Net Income / (Loss)	-93	-82	17	12	-21	25	36	18	50	78	70
Depreciation Expense	57	56	56	59	66	60	60	54	49	43	48
Amortization Expense	4.66	6.80	0.93	1.44	26	6.81	6.88	5.03	3.72	3.89	4.06
Non-Cash Adjustments To Reconcile Net Income	133	32	27	39	59	21	23	90	38	-2.84	40
Changes in Operating Assets and Liabilities, net	34	-17	-61	31	-12	-105	-42	-49	-10	-149	-183
Net Cash From Investing Activities	-32	-20	-6.47	-21	-16	-18	-27	-22	-45	-22	-123
Net Cash From Continuing Investing Activities	-32	-20	-6.47	-21	-16	-18	-27	-22	-45	-22	-123
Purchase of Property, Plant & Equipment	-12	-10	-11	-17	-22	-14	-27	-15	-43	-14	-46
Acquisitions	-20	-9.70	-0.75	-3.60	-0.60	-4.20	-0.90	-7.41	-3.00	-7.85	-77
Net Cash From Financing Activities	-101	-23	-35	-92	-61	-39	-42	59	-10	-59	79
Net Cash From Continuing Financing Activities	-101	-23	-35	-92	-61	-39	-42	59	-10	-59	79
Repayment of Debt	-424	-63	-27	-87	-56	-236	-17	-2,628	-6.12	-143	-6.19
Issuance of Debt	327	48	-	-	-	218	-	2,695	-	135	100
Other Financing Activities, net	-0.11	-7.18	0.20	0.42	-0.24	-22	-24	-7.77	-4.00	-51	-14
Effect of Exchange Rate Changes	0.20	-0.17	-0.10	0.01	-0.74	-0.47	-0.31	-0.69	-0.21	-1.02	-0.16
Cash Interest Paid	56	65	72	66	61	56	56	44	41	56	35
Cash Income Taxes Paid	2.07	4.57	15	-1.15	6.16	-3.61	8.95	5.01	3.75	2.45	-2.14

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	1,342	4,353	3,666	4,006	3,940	3,799	3,473	3,501	3,678
Total Current Assets	772	1,287	1,210	1,552	1,520	1,412	1,378	1,588	1,911
Cash & Equivalents	74	213	151	341	248	26	92	111	282
Restricted Cash	3.76	5.39	1.63	5.74	8.95	9.25	7.57	7.87	29
Accounts Receivable	368	482	606	640	664	742	615	776	896
Inventories, net	284	457	381	491	489	531	581	612	606
Prepaid Expenses	42	128	70	73	110	104	83	81	98
Plant, Property, & Equipment, net	487	544	478	478	514	470	448	425	443
Total Noncurrent Assets	83	2,522	2,109	1,977	1,905	1,918	1,647	1,489	1,324
Noncurrent Note & Lease Receivables	-	0.00	123	68	64	63	59	56	53
Goodwill	26	426	420	523	593	599	599	597	595
Intangible Assets	45	1,655	1,383	1,305	1,167	1,096	890	732	563
Other Noncurrent Operating Assets	11	68	184	81	81	159	99	102	112
Total Liabilities & Shareholders' Equity	1,342	4,353	3,666	4,006	3,940	3,799	3,473	3,501	3,678
Total Liabilities	1,717	3,456	3,319	3,649	3,556	3,590	3,411	3,546	3,672
Total Current Liabilities	297	554	550	677	677	753	847	1,130	882
Short-Term Debt	89	22	21	45	31	90	213	324	6.76
Accounts Payable	207	532	513	619	573	541	542	758	817
Other Current Liabilities	-	0.00	18	16	76	122	91	48	58
Total Noncurrent Liabilities	1,421	2,903	2,769	2,972	2,879	2,838	2,565	2,416	2,791
Long-Term Debt	1,355	2,631	2,609	2,772	2,718	2,592	2,427	2,162	2,565
Asset Retirement Reserve & Litigation Obligation	-	-	-	-	-	-	0.32	85	72
Other Noncurrent Operating Liabilities	7.79	39	98	201	100	185	78	112	154
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	0.00	12	17	25	41	65	77
Total Equity & Noncontrolling Interests	-376	896	347	345	367	184	20	-110	-71
Total Preferred & Common Equity	-386	505	232	303	360	298	20	-109	-71
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-386	505	232	303	360	298	20	-109	-71
Common Stock	11	533	610	631	661	695	542	563	575
Retained Earnings	-383	-21	-378	-287	-276	-406	-490	-607	-535
Accumulated Other Comprehensive Income / (Loss)	-14	-7.76	-0.07	-41	-25	9.94	-32	-66	-111
Noncontrolling Interest	10	392	115	42	6.63	-114	0.23	-0.25	-0.54

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	3,627	3,701	3,687	3,456	3,510	3,461	3,365	3,423	3,600	3,540	3,776
Total Current Assets	1,307	1,422	1,456	1,380	1,485	1,513	1,510	1,585	1,838	1,798	1,947
Cash & Equivalents	145	109	87	47	44	74	59	72	201	198	128
Restricted Cash	6.40	-	-	-	-	-	-	-	35	-	8.64
Accounts Receivable	546	675	693	670	779	757	755	809	886	851	1,021
Inventories, net	529	551	576	571	576	596	601	609	615	642	678
Prepaid Expenses	81	82	91	87	82	82	89	85	102	103	112
Plant, Property, & Equipment, net	463	459	452	440	425	431	427	440	435	445	457
Total Noncurrent Assets	1,857	1,820	1,779	1,637	1,599	1,517	1,428	1,398	1,326	1,298	1,372
Noncurrent Note & Lease Receivables	62	62	61	60	58	58	56	55	54	53	52
Goodwill	599	599	599	599	599	598	597	597	596	594	593
Intangible Assets	1,055	1,015	983	859	820	780	689	650	588	535	588
Other Noncurrent Operating Assets	140	144	137	119	122	81	85	96	88	116	139
Total Liabilities & Shareholders' Equity	3,627	3,701	3,687	3,456	3,510	3,461	3,365	3,423	3,600	3,540	3,776
Total Liabilities	3,464	3,518	3,496	3,473	3,514	3,495	3,425	3,470	3,642	3,500	3,659
Total Current Liabilities	704	777	761	834	1,114	1,095	1,076	1,107	862	728	883
Short-Term Debt	130	150	107	213	436	365	322	321	7.20	6.20	106
Accounts Payable	482	534	561	576	632	684	695	730	800	696	743
Other Current Liabilities	92	90	90	43	44	47	59	56	55	26	34
Total Noncurrent Liabilities	2,761	2,741	2,735	2,639	2,400	2,399	2,349	2,362	2,780	2,772	2,776
Long-Term Debt	2,602	2,549	2,542	2,378	2,178	2,170	2,154	2,146	2,567	2,566	2,564
Asset Retirement Reserve & Litigation Obligation	-	-	-	85	85	85	73	74	74	70	71
Other Noncurrent Operating Liabilities	99	191	193	175	137	144	122	142	83	137	141
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	28	32	37	47	53	60	73	66	68	86	84
Total Equity & Noncontrolling Interests	135	151	154	-64	-57	-94	-132	-113	-110	-46	33
Total Preferred & Common Equity	294	318	331	-64	-57	-93	-132	-112	-109	-45	33
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	294	318	331	-64	-57	-93	-132	-112	-109	-45	33
Common Stock	704	711	719	542	549	556	549	558	567	539	549
Retained Earnings	-413	-401	-392	-582	-576	-576	-595	-572	-570	-473	-415
Accumulated Other Comprehensive Income / (Loss)	3.76	8.08	3.87	-24	-30	-74	-86	-97	-106	-112	-101
Noncontrolling Interest	-160	-167	-177	0.10	-0.02	-0.14	-0.33	-0.42	-0.50	-0.56	0.00

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	314,362,920.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	314,362,920.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	0.23
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	278	242	-14	-174	64	98	-66	143	175	362
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-2.27%	5.26%	7.17%	14.17%
Earnings before Interest and Taxes (EBIT)	270	245	-39	-52	110	168	-89	211	204	412
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	306	295	114	198	354	410	159	452	469	658
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-804	-2,336	180	256	-13	-49	398	456	420
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1,046	3,369	3,015	2,823	2,933	2,916	2,661	2,380	2,322
Increase / (Decrease) in Invested Capital	0.00	1,046	2,323	-354	-192	111	-17	-255	-281	-58
Book Value per Share	$0.00	$0.00	$1.69	$0.78	$1.01	$1.20	$0.98	$0.06	($0.35)	($0.23)
Tangible Book Value per Share	$0.00	$0.00	($5.28)	($5.25)	($5.08)	($4.64)	($4.60)	($4.79)	($4.64)	($3.91)
Total Capital	0.00	1,109	3,588	3,039	3,174	3,193	2,952	2,760	2,498	2,633
Total Debt	0.00	1,485	2,691	2,692	2,817	2,809	2,743	2,699	2,543	2,627
Total Long-Term Debt	0.00	1,395	2,670	2,671	2,772	2,778	2,653	2,486	2,219	2,620
Net Debt	0.00	1,407	2,473	2,539	2,470	2,552	2,707	2,600	2,424	2,316
Capital Expenditures (CapEx)	123	95	58	47	62	51	49	47	60	97
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	487	536	528	573	617	714	645	664	725
Debt-free Net Working Capital (DFNWC)	0.00	565	755	681	920	873	749	744	782	1,036
Net Working Capital (NWC)	0.00	475	733	660	875	843	659	531	458	1,030
Net Nonoperating Expense (NNE)	68	73	188	429	-4.77	78	188	192	248	234
Net Nonoperating Obligations (NNO)	0.00	1,422	2,473	2,668	2,466	2,550	2,707	2,600	2,424	2,316
Total Depreciation and Amortization (D&A)	36	51	154	250	244	243	249	241	265	246
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.62	$0.07	($0.86)	($0.48)	($0.38)	$0.23
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	298.69M	299.23M	147.44M	148.92M	150.94M	176.14M	308.98M	313.37M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.61	$0.07	($0.86)	($0.48)	($0.38)	$0.22
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	298.69M	299.23M	148.91M	151.82M	150.94M	176.14M	308.98M	324.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	127.25M	132.11M	299.82M	301.54M	303.62M	307.01M	309.97M	314.63M
Normalized Net Operating Profit after Tax (NOPAT)	292	223	195	-97	78	125	134	157	243	366
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	314,362,920.00	314,629,101.00	319,022,792.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	314,362,920.00	314,629,101.00	319,022,792.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	0.11	0.20	0.18
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.18%	18.23%	17.15%	13.29%	18.40%	5.50%	3.24%	11.68%	-	3.90%	9.89%
EBITDA Growth	-23.67%	-54.05%	1.81%	5.92%	76.98%	207.35%	23.24%	0.09%	-	14.09%	-3.21%
EBIT Growth	-57.41%	-124.62%	6.96%	9.57%	174.35%	1,061.66%	35.63%	9.91%	-	45.14%	7.89%
NOPAT Growth	-60.61%	-131.19%	-1.93%	-17.93%	434.02%	976.08%	-2.35%	-27.27%	-	109.29%	65.92%
Net Income Growth	-1,493.44%	-709.17%	-43.45%	-53.03%	77.78%	130.14%	112.13%	54.22%	-	216.84%	95.49%
EPS Growth	-1,800.00%	-500.00%	-75.00%	-100.00%	82.46%	113.33%	250.00%	0.00%	-	375.00%	157.14%
Operating Cash Flow Growth	683.13%	-103.16%	449.55%	74.20%	-13.06%	267.98%	111.36%	-16.45%	-	-461.00%	-125.35%
Free Cash Flow Firm Growth	526.92%	17.47%	20.41%	54.67%	26.21%	-10.99%	4.52%	-69.36%	-	-67.31%	-161.42%
Invested Capital Growth	-8.75%	-9.91%	-7.51%	-11.83%	-10.57%	-6.92%	-8.70%	-2.93%	-	2.52%	13.31%
Revenue Q/Q Growth	-0.49%	6.84%	6.46%	0.10%	3.99%	-4.80%	4.18%	8.28%	-	-11.27%	10.20%
EBITDA Q/Q Growth	-41.18%	-38.77%	210.08%	-0.91%	-1.72%	16.19%	13.88%	-19.45%	-	11.99%	-3.38%
EBIT Q/Q Growth	-77.13%	-158.13%	977.12%	-6.03%	-42.74%	103.75%	23.71%	-23.85%	-	22.94%	-8.04%
NOPAT Q/Q Growth	-87.96%	-175.71%	1,144.14%	-13.81%	-21.63%	24.21%	16.38%	-35.80%	-	37.17%	-7.74%
Net Income Q/Q Growth	-472.88%	12.50%	120.55%	-29.96%	-276.42%	218.69%	44.65%	-49.08%	-	57.34%	-10.75%
EPS Q/Q Growth	-1,050.00%	47.37%	106.67%	-100.00%	0.00%	140.00%	75.00%	-85.71%	-	90.00%	-5.26%
Operating Cash Flow Q/Q Growth	66.89%	-103.25%	999.25%	257.50%	-16.71%	-93.73%	1,031.47%	41.32%	-	-120.52%	20.56%
Free Cash Flow Firm Q/Q Growth	4.40%	-25.36%	6.07%	36.92%	-14.81%	-28.06%	24.55%	-59.86%	-	-50.40%	-334.01%
Invested Capital Q/Q Growth	-3.12%	-1.51%	1.48%	-5.48%	-1.75%	-1.23%	-0.47%	0.49%	-	3.79%	10.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.77%	36.11%	35.62%	38.37%	35.98%	36.80%	39.51%	34.92%	-	44.31%	42.01%
EBITDA Margin	12.72%	6.98%	20.32%	20.12%	19.02%	23.21%	25.37%	18.87%	-	25.48%	22.34%
Operating Margin	2.30%	-1.63%	13.60%	12.64%	10.38%	14.43%	15.37%	8.97%	-	19.62%	16.30%
EBIT Margin	2.74%	-1.49%	12.27%	11.52%	6.34%	13.58%	16.12%	11.34%	-	18.97%	15.83%
Profit (Net Income) Margin	-15.13%	-12.39%	2.39%	1.67%	-2.84%	3.54%	4.92%	2.31%	-	10.80%	8.74%
Tax Burden Percent	111.84%	108.15%	82.27%	76.23%	135.40%	65.67%	68.86%	-347.16%	-	97.29%	98.06%
Interest Burden Percent	-494.09%	769.14%	23.69%	19.06%	-33.06%	39.70%	44.27%	-5.87%	-	58.50%	56.33%
Effective Tax Rate	0.00%	0.00%	17.73%	23.77%	0.00%	34.33%	31.14%	0.00%	-	2.71%	1.94%
Return on Invested Capital (ROIC)	1.38%	-1.07%	10.90%	9.99%	8.05%	11.00%	12.32%	7.72%	-	24.43%	19.97%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.51%	-3.93%	8.51%	7.76%	5.11%	9.33%	10.66%	6.44%	-	21.92%	17.63%
Return on Net Nonoperating Assets (RNNOA)	-49.29%	-139.92%	245.25%	246.67%	1,532.19%	-608.18%	-1,039.60%	-411.40%	-	-5,388.11%	1,234.51%
Return on Equity (ROE)	-47.91%	-140.99%	256.15%	256.66%	1,540.24%	-597.18%	-1,027.28%	-403.68%	-	-5,363.68%	1,254.48%
Cash Return on Invested Capital (CROIC)	14.28%	14.61%	12.39%	17.65%	18.09%	15.43%	17.91%	15.56%	-	15.75%	6.99%
Operating Return on Assets (OROA)	1.80%	-1.05%	8.84%	8.64%	5.08%	11.27%	13.27%	9.43%	-	16.73%	13.71%
Return on Assets (ROA)	-9.96%	-8.73%	1.72%	1.26%	-2.28%	2.94%	4.05%	1.92%	-	9.52%	7.57%
Return on Common Equity (ROCE)	-56.42%	-223.40%	373.47%	386.42%	-8,220.83%	-1,535.39%	-3,429.44%	-1,079.74%	-	-48,842.44%	-1,412.43%
Return on Equity Simple (ROE_SIMPLE)	0.00%	188.79%	231.80%	156.78%	0.00%	-24.62%	0.00%	0.00%	-	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	9.94	-7.52	79	68	53	66	77	49	101	138	127
NOPAT Margin	1.61%	-1.14%	11.19%	9.64%	7.26%	9.48%	10.59%	6.28%	-	19.09%	15.98%
Net Nonoperating Expense Percent (NNEP)	3.89%	2.86%	2.40%	2.23%	2.94%	1.67%	1.66%	1.28%	-	2.51%	2.34%
Return On Investment Capital (ROIC_SIMPLE)	0.37%	-	-	-	2.18%	2.81%	3.26%	1.95%	3.93%	5.46%	4.71%
Cost of Revenue to Revenue	69.23%	63.89%	64.38%	61.63%	64.02%	63.20%	60.49%	65.08%	-	55.69%	57.99%
SG&A Expenses to Revenue	17.67%	17.08%	16.60%	16.90%	17.62%	17.01%	17.15%	17.57%	-	19.22%	18.68%
R&D to Revenue	8.09%	5.96%	5.14%	8.70%	8.23%	6.01%	6.90%	8.39%	-	5.53%	5.16%
Operating Expenses to Revenue	28.47%	37.74%	22.01%	25.73%	25.61%	22.37%	24.14%	25.96%	-	24.68%	25.71%
Earnings before Interest and Taxes (EBIT)	17	-9.82	86	81	46	94	117	89	111	137	126
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	78	46	143	141	139	161	184	148	164	184	178
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	94.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	167.22
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Price to Revenue (P/Rev)	0.78	0.75	0.75	0.96	0.88	0.92	0.89	1.07	-	1.28	1.77
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	751.28	532.87	-	32.03	35.09
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.13%	0.19%	-	3.12%	2.85%
Enterprise Value to Invested Capital (EV/IC)	1.69	1.76	1.79	2.10	2.08	2.16	2.14	2.38	-	2.64	3.07
Enterprise Value to Revenue (EV/Rev)	1.88	1.78	1.76	1.90	1.77	1.80	1.75	1.91	-	2.09	2.61
Enterprise Value to EBITDA (EV/EBITDA)	9.96	11.28	11.54	12.58	10.54	8.80	8.16	9.15	-	9.36	12.07
Enterprise Value to EBIT (EV/EBIT)	21.32	27.57	27.43	29.26	24.28	16.52	14.76	16.17	-	14.02	17.56
Enterprise Value to NOPAT (EV/NOPAT)	31.47	39.95	37.50	38.78	28.32	25.25	23.14	18.66	-	14.67	16.76
Enterprise Value to Operating Cash Flow (EV/OCF)	13.03	22.10	18.15	16.29	16.75	16.57	14.23	17.10	-	20.83	40.54
Enterprise Value to Free Cash Flow (EV/FCFF)	11.31	11.44	13.87	11.17	10.84	13.52	11.38	15.09	-	16.99	46.65
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	44.03	-155.98	-642.51	-75.25	-57.09	-41.69	-52.80	-62.34	-	64.39	22.83
Long-Term Debt to Equity	40.55	-143.18	-535.43	-64.42	-49.82	-36.27	-45.93	-62.17	-	64.23	21.92
Financial Leverage	19.64	35.60	28.83	31.78	299.68	-65.16	-97.51	-63.93	-	-245.81	70.04
Leverage Ratio	26.91	48.65	40.33	45.33	415.96	-89.76	-136.48	-93.08	-	-355.11	102.48
Compound Leverage Factor	-132.96	374.20	9.55	8.64	-137.50	-35.64	-60.42	5.47	-	-207.75	57.72
Debt to Total Capital	97.78%	100.65%	100.16%	101.35%	101.78%	102.46%	101.93%	101.63%	-	98.47%	95.80%
Short-Term Debt to Total Capital	7.72%	8.26%	16.69%	14.58%	12.98%	13.32%	13.27%	0.28%	-	0.24%	3.80%
Long-Term Debt to Total Capital	90.06%	92.38%	83.46%	86.76%	88.81%	89.14%	88.66%	101.35%	-	98.23%	92.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.50%	1.83%	2.05%	2.39%	2.59%	2.99%	2.70%	2.60%	-	3.27%	3.01%
Common Equity to Total Capital	0.72%	-2.48%	-2.20%	-3.74%	-4.37%	-5.45%	-4.63%	-4.23%	-	-1.74%	1.18%
Debt to EBITDA	5.97	6.56	6.58	6.26	5.42	4.29	4.03	4.29	-	3.78	3.96
Net Debt to EBITDA	5.75	6.45	6.47	6.07	5.17	4.18	3.91	3.91	-	3.49	3.76
Long-Term Debt to EBITDA	5.50	6.02	5.48	5.36	4.73	3.73	3.50	4.28	-	3.77	3.80
Debt to NOPAT	18.87	23.25	21.38	19.29	14.57	12.29	11.43	8.76	-	5.92	5.50
Net Debt to NOPAT	18.17	22.83	21.03	18.72	13.89	11.99	11.10	7.97	-	5.47	5.22
Long-Term Debt to NOPAT	17.38	21.34	17.82	16.51	12.71	10.69	9.94	8.73	-	5.91	5.28
Altman Z-Score	1.02	0.99	1.05	1.21	1.17	1.30	1.32	1.52	-	1.83	2.03
Noncontrolling Interest Sharing Ratio	-17.75%	-58.45%	-45.80%	-50.56%	633.73%	-157.11%	-233.84%	-167.47%	-	-810.61%	212.59%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.63	1.65	1.33	1.38	1.41	1.40	1.43	2.13	-	2.47	2.20
Quick Ratio	0.83	0.86	0.74	0.76	0.78	0.76	0.80	1.26	-	1.44	1.30
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	265	270	287	393	334	241	300	120	159	79	-184
Operating Cash Flow to CapEx	1,151.82%	-43.84%	370.49%	828.51%	525.63%	54.48%	326.82%	787.04%	-	-192.95%	-46.60%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.84	-	22.41	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.78	-	-7.62	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.30	-	-11.57	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.66	0.70	0.72	0.75	0.80	0.83	0.82	0.83	-	0.88	0.87
Accounts Receivable Turnover	3.53	4.10	3.57	3.70	4.02	3.97	3.59	3.57	-	3.79	3.41
Inventory Turnover	2.83	2.94	3.00	2.96	2.97	3.06	3.00	3.07	-	3.01	2.94
Fixed Asset Turnover	5.22	5.53	5.87	6.07	6.40	6.53	6.59	6.78	-	6.99	6.95
Accounts Payable Turnover	2.91	3.05	2.90	2.78	2.73	2.82	2.61	2.50	-	2.69	2.57
Days Sales Outstanding (DSO)	103.46	88.96	102.11	98.67	90.85	91.90	101.58	102.17	-	96.23	107.13
Days Inventory Outstanding (DIO)	129.03	124.28	121.79	123.51	122.85	119.37	121.57	119.07	-	121.42	124.15
Days Payable Outstanding (DPO)	125.61	119.54	126.07	131.14	133.75	129.38	139.79	145.93	-	135.85	142.15
Cash Conversion Cycle (CCC)	106.88	93.70	97.82	91.04	79.96	81.89	83.35	75.31	-	81.80	89.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,661	2,525	2,563	2,422	2,380	2,351	2,340	2,351	2,322	2,410	2,651
Invested Capital Turnover	0.86	0.94	0.97	1.04	1.11	1.16	1.16	1.23	-	1.28	1.25
Increase / (Decrease) in Invested Capital	-255	-278	-208	-325	-281	-175	-223	-71	-58	59	311
Enterprise Value (EV)	4,502	4,451	4,583	5,095	4,943	5,086	4,997	5,605	-	6,370	8,140
Market Capitalization	1,861	1,860	1,960	2,575	2,454	2,598	2,536	3,144	-	3,911	5,522
Book Value per Share	$0.06	($0.21)	($0.19)	($0.30)	($0.35)	($0.42)	($0.36)	($0.35)	($0.23)	($0.14)	$0.10
Tangible Book Value per Share	($4.79)	($4.96)	($4.78)	($4.76)	($4.64)	($4.58)	($4.34)	($4.12)	($3.91)	($3.73)	($3.60)
Total Capital	2,760	2,574	2,609	2,501	2,498	2,416	2,421	2,587	2,633	2,612	2,787
Total Debt	2,699	2,590	2,613	2,534	2,543	2,476	2,468	2,629	2,627	2,572	2,670
Total Long-Term Debt	2,486	2,378	2,178	2,170	2,219	2,154	2,146	2,622	2,620	2,566	2,564
Net Debt	2,600	2,544	2,569	2,460	2,424	2,417	2,396	2,393	2,316	2,374	2,534
Capital Expenditures (CapEx)	12	10	11	17	22	14	26	15	42	14	46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	645	712	763	709	664	697	727	748	725	878	1,034
Debt-free Net Working Capital (DFNWC)	744	758	807	783	782	756	799	984	1,036	1,076	1,170
Net Working Capital (NWC)	531	546	371	418	458	435	478	976	1,030	1,070	1,064
Net Nonoperating Expense (NNE)	103	74	62	56	74	41	41	31	51	60	58
Net Nonoperating Obligations (NNO)	2,600	2,542	2,567	2,456	2,424	2,410	2,386	2,393	2,316	2,370	2,534
Total Depreciation and Amortization (D&A)	62	56	57	60	93	67	67	59	53	47	52
Debt-free, Cash-free Net Working Capital to Revenue	26.96%	28.53%	29.36%	26.44%	23.76%	24.64%	25.49%	25.47%	-	28.84%	33.15%
Debt-free Net Working Capital to Revenue	31.10%	30.39%	31.05%	29.20%	28.00%	26.73%	28.00%	33.51%	-	35.33%	37.52%
Net Working Capital to Revenue	22.20%	21.87%	14.29%	15.60%	16.39%	15.36%	16.74%	33.27%	-	35.13%	34.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.11	$0.20	$0.18
Adjusted Weighted Average Basic Shares Outstanding	176.14M	307.28M	309.12M	309.65M	308.98M	311.05M	313.74M	314.17M	313.37M	316.02M	319.20M
Adjusted Diluted Earnings per Share	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.10	$0.19	$0.18
Adjusted Weighted Average Diluted Shares Outstanding	176.14M	307.28M	318.96M	309.65M	308.98M	323.96M	322.36M	324.75M	324.81M	328.93M	328.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	307.01M	308.65M	309.54M	309.84M	309.97M	313.42M	314.08M	314.36M	314.63M	319.02M	319.35M
Normalized Net Operating Profit after Tax (NOPAT)	2.42	60	79	67	55	66	77	49	103	144	143
Normalized NOPAT Margin	0.39%	9.05%	11.30%	9.53%	7.48%	9.53%	10.65%	6.29%	-	19.96%	17.98%
Pre Tax Income Margin	-13.53%	-11.46%	2.91%	2.20%	-2.10%	5.39%	7.14%	-0.67%	-	11.10%	8.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.84	-	39.04	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.57	-	39.29	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.36	-	35.10	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.09	-	35.35	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-145.48%	-44.27%	-33.19%	-11.91%	-26.81%	59.46%	0.00%	0.00%	-	0.00%	0.00%
Augmented Payout Ratio	-145.48%	-44.27%	-33.19%	-11.91%	-26.81%	59.46%	0.00%	0.00%	-	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Amneal Pharmaceuticals (NASDAQ: AMRX) has shown strong revenue and margin improvement across the reported quarters from 2023 through the second quarter of 2026. However, the latest quarter also highlights continued pressure from working-capital needs, acquisitions and a heavily leveraged balance sheet.

Revenue growth has been consistent. Second-quarter revenue increased to $796.2 million in 2026 from $724.5 million in 2025, $701.8 million in 2024 and $599.0 million in 2023. That represents approximately 33% growth over the three-year period. Gross profit also rose to $334.5 million from $286.3 million a year earlier, while the gross margin expanded to approximately 42.0% from 39.5%.

Profitability has improved substantially. Operating income reached $129.8 million in Q2 2026, compared with $111.4 million in Q2 2025 and $80.1 million in Q2 2023. The operating margin improved to approximately 16.3%. Net income attributable to common shareholders rose to $57.7 million, or $0.18 per diluted share, from $22.4 million, or $0.07 per share, in the restated year-ago quarter.

Revenue momentum: Q2 2026 revenue grew approximately 9.9% year over year and 10.2% from Q1 2026, continuing a multiyear upward trend.
Margin expansion: Gross margin improved from approximately 35.6% in Q2 2024 to 39.5% in Q2 2025 and 42.0% in Q2 2026.
Stronger operating earnings: Operating income increased approximately 16.5% year over year, and the operating margin reached about 16.3%.
Improved shareholder earnings: Diluted EPS increased to $0.18 from $0.07 in the prior-year quarter, although it remained below the $0.19 reported in Q1 2026.
Balance-sheet equity recovery: Total common equity improved from negative $131.7 million in Q1 2025 and negative $109.5 million in Q3 2025 to positive $33.0 million at June 30, 2026.
Higher cash relative to last year: Cash and equivalents were $127.6 million at the end of Q2 2026, up from $71.5 million at the end of Q2 2025. Including restricted cash, liquidity totaled approximately $136.3 million.
Operating expenses remain elevated: SG&A rose to $148.7 million in Q2 2026 from $124.3 million in Q2 2025, while research and development spending increased modestly to $41.1 million.
Acquisition and investment activity: Amneal spent $77.2 million on acquisitions and $45.6 million on capital expenditures in Q2 2026. These investments could support future growth but reduce near-term free cash flow.
Negative operating cash flow: Operating activities used $21.2 million in Q2 2026 after using $26.7 million in Q1. This compares with $83.8 million of operating cash flow in Q2 2025 and $118.5 million in Q3 2025.
High leverage and refinancing risk: Short- and long-term debt totaled approximately $2.67 billion at June 30, 2026, compared with about $2.46 billion a year earlier. Q2 also included a $100 million debt issuance, suggesting financing remains important to liquidity management.

Working capital is the main reason reported earnings have not translated into cash recently. Accounts receivable increased to approximately $1.02 billion in Q2 2026 from $809.2 million in Q2 2025, while inventories increased to $678.0 million from $609.0 million. The combined increase in receivables and inventory ties up capital and contributed to a $183.0 million unfavorable change in operating assets and liabilities during the latest quarter.

Cash generation has also been volatile. Amneal produced positive operating cash flow in Q2 2024, Q3 2024, Q2 2025 and Q4 2025, but reported negative operating cash flow in both Q1 and Q2 2026. After capital expenditures and acquisitions, investing cash outflow reached $122.7 million in Q2 2026. Financing provided $79.4 million, primarily because of the $100 million debt issuance, but total cash still declined by $64.8 million during the quarter.

The balance sheet has improved from the deeply negative common-equity position seen during 2024 and early 2025, but it remains highly leveraged. Long-term debt was approximately $2.56 billion, compared with only $127.6 million of unrestricted cash. Accounts payable also stood at $743.3 million, meaning the company must continue generating cash from operations and managing supplier obligations carefully.

Overall, the statements show a company with improving revenue, gross margins and reported earnings, but with a less convincing cash-flow profile in the first half of 2026. For investors, the key indicators to monitor are whether working capital normalizes, whether operating cash flow returns to positive territory and whether Amneal can reduce debt without relying on additional borrowing.

09/05/26 07:46 AM ETAI Generated. May Contain Errors.

Amneal Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Amneal Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Amneal Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $127.93 million in 2025, falling from $209.43 million in 2016. The previous period was -$73.88 million in 2024. See Amneal Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Amneal Pharmaceuticals' total operating income in 2025 was $394.10 million, based on the following breakdown:

Total Gross Profit: $1.11 billion
Total Operating Expenses: $719.21 million

Over the last 9 years, Amneal Pharmaceuticals' total revenue changed from $1.02 billion in 2016 to $3.02 billion in 2025, a change of 196.5%.

Amneal Pharmaceuticals' total liabilities were at $3.67 billion at the end of 2025, a 3.6% increase from 2024, and a 113.8% increase since 2017.

In the past 8 years, Amneal Pharmaceuticals' cash and equivalents has ranged from $25.98 million in 2022 to $341.38 million in 2020, and is currently $282.03 million as of their latest financial filing in 2025.

Over the last 9 years, Amneal Pharmaceuticals' book value per share changed from 0.00 in 2016 to -0.23 in 2025, a change of -22.5%.

Related Companies

Financial statements for NASDAQ:AMRX last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Financials

Financials Breakdown Chart

Key Financial Trends

Amneal Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Financials

Annual Income Statements for Amneal Pharmaceuticals

Quarterly Income Statements for Amneal Pharmaceuticals

Annual Cash Flow Statements for Amneal Pharmaceuticals

Quarterly Cash Flow Statements for Amneal Pharmaceuticals

Annual Balance Sheets for Amneal Pharmaceuticals

Quarterly Balance Sheets for Amneal Pharmaceuticals

Annual Metrics And Ratios for Amneal Pharmaceuticals

Quarterly Metrics And Ratios for Amneal Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Amneal Pharmaceuticals Financials - Frequently Asked Questions

When does Amneal Pharmaceuticals' financial year end?

How has Amneal Pharmaceuticals' net income changed over the last 9 years?

What is Amneal Pharmaceuticals' operating income?

How has Amneal Pharmaceuticals' revenue changed over the last 9 years?

How much debt does Amneal Pharmaceuticals have?

How much cash does Amneal Pharmaceuticals have?

How has Amneal Pharmaceuticals' book value per share changed over the last 9 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools